26754-37-0

Basic information

• Product Name: erythronolide A
• Synonyms: (3R)-14β-Ethyl-4β,6β,7α,12α,13α-pentahydroxy-3α,5β,7,9β,11α,13-hexamethyloxacyclotetradecane-2,10-dione;erythronolide A
• CAS NO: 26754-37-0
• Molecular Formula: C₂₁H₃₈O₈
• Molecular Weight: 418.52162
• Mol File: 26754-37-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 590.7°Cat760mmHg
• Flash Point: 196.7°C
• Appearance: /
• Density: 1.125g/cm³
• Vapor Pressure: 2.06E-16mmHg at 25°C
• Refractive Index: 1.488
• CAS DataBase Reference: erythronolide A(CAS DataBase Reference)
• NIST Chemistry Reference: erythronolide A(26754-37-0)
• EPA Substance Registry System: erythronolide A(26754-37-0)

Safety Data

• Hazardous Substances Data: 26754-37-0(Hazardous Substances Data)

Usage

General Description

Erythronolide A is a macrolide antibiotic compound that is a precursor to the antibiotic erythromycin. It is a polyketide that is produced by various species of Saccharopolyspora bacteria through a complex biosynthetic pathway. Erythronolide A consists of a 14-membered macrocyclic lactone ring with several methyl and hydroxyl groups attached. Erythronolide A is an important intermediate in the industrial production of erythromycin and related antibiotics, which are commonly used to treat bacterial infections. The structure of erythronolide A has been studied extensively due to its role in antibiotic synthesis and its potential for medicinal chemistry applications.

InChI:InChI=1/C21H38O8/c1-8-14-21(7,28)18(25)11(3)15(22)10(2)9-20(6,27)17(24)12(4)16(23)13(5)19(26)29-14/h10-14,16-18,23-25,27-28H,8-9H2,1-7H3/t10-,11+,12+,13-,14-,16+,17-,18-,20-,21-/m1/s1

Upstream product

• 104331-69-3 5-O-(t-butyldiphenylsilyl)-1-deoxy-3,4-O-isopropyldene-2-C-vinyl-D-ribitol 
• 128879-55-0 (2R,4R,5S,6R)-4-[(S)-2-((S)-Benzenesulfinyl)-1-methyl-ethyl]-6-[(1S,2R)-1,2-bis-(tert-butyl-dimethyl-silanyloxy)-1-methyl-butyl]-2-(4-methoxy-phenyl)-5-methyl-[1,3]dioxane 
• 128879-55-0 (2R,4R,5S,6R)-4-[(S)-2-((R)-Benzenesulfinyl)-1-methyl-ethyl]-6-[(1S,2R)-1,2-bis-(tert-butyl-dimethyl-silanyloxy)-1-methyl-butyl]-2-(4-methoxy-phenyl)-5-methyl-[1,3]dioxane 
• 129269-51-8 (2R,3R,4S,5R)-4,5-Bis-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-heptanal 
• 129245-13-2 (2S,3R,4S,5R)-4,5-Bis-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-heptan-1-ol 
• 129245-10-9 Benzoic acid (2S,3R,4R,5R)-5-hydroxy-3-(4-methoxy-benzyloxy)-4-methoxymethoxy-2,4-dimethyl-heptyl ester 
• 129245-11-0 Benzoic acid (2S,3R,4R,5R)-4,5-dihydroxy-3-(4-methoxy-benzyloxy)-2,4-dimethyl-heptyl ester 
• 129269-50-7 (2S,3R,4R,5R)-3-(4-Methoxy-benzyloxy)-4-methoxymethoxy-2,4-dimethyl-heptane-1,5-diol 
• 124928-79-6 (4S,5R)-5-((R)-1-Benzyloxy-propyl)-2,2,5-trimethyl-[1,3]dioxolane-4-carbaldehyde 
• 105545-14-0 (R)-2-((4S,5S,6R)-6-{(1R,3R)-3-[(4S,5S,6R)-6-((1R,2R)-1,2-Dihydroxy-1-methyl-butyl)-2,2,5-trimethyl-[1,3]dioxan-4-yl]-1-hydroxy-1-methyl-butyl}-2,2,5-trimethyl-[1,3]dioxan-4-yl)-thiopropionic acid S-pyridin-2-yl ester 
• 105545-12-8 (R)-2-((4S,5S,6R)-6-{(1R,3R)-3-[(4S,5S,6R)-6-((1R,2R)-2-Acetoxy-1-hydroxy-1-methyl-butyl)-2,2,5-trimethyl-[1,3]dioxan-4-yl]-1-hydroxy-1-methyl-butyl}-2,2,5-trimethyl-[1,3]dioxan-4-yl)-propionic acid 
• 105544-91-0 3-O-benzyl-7-O-(t-butyldiphenylsilyl)-1,2-dideoxy-4,5-O-isopropylidene-4-C-methyl-D-manno-heptitol 
• 105544-89-6 3-O-benzyl-7-O-(t-butyldiphenylsilyl)-1,2-dideoxy-5,6-O-isopropylidene-4-C-methyl-D-manno-heptitol 
• 105545-11-7 13-O-acetyl-2,4,7,8,10,14,15-heptadeoxy-3,5;9,11-di-O-isopropylidene-2,4,6,8,10,12-hexa-C-methyl-D-arabino-D-gluco-L-ido-pentadecitol 

Downstream Products

• 15562-19-3 (9R)-dihydroerythronolide 
• 15562-19-3 9S-Dihydroerythronolide A aglycon 

Relevant articles and documents

Preparation method and application of 14-membered ring and 16-membered ring macrolide derivatives

The invention provides a preparation method and application of 14-membered ring and 16-membered ring macrolide derivatives. Experiments prove that the prepared 14-membered ring and 16-membered ring macrolide derivatives are medicines with specific intestinal motility promoting activity and without antibiotic activity. According to the preparation method and the application of the 14-membered ringand 16-membered ring macrolide derivatives, the 14-membered ring and 16-membered ring macrolide derivatives have a very good effect of promoting the digestive tract motility and can enhance the intestinal peristalsis, increase the defecation amount and speed up passing of intestinal contents.

Total synthesis of erythronolide A by MgII-mediated cycloadditions of nitrile oxides

(Chemical Equation Presented) A cycloaddition comes of age: The focal points of a stereoselective total synthesis of erythronolide A (see structure) are two MgII-mediated cycloadditions of nitrile oxides. Of broader significance, the strategy not only facilitates the synthesis of specific polyketide targets (i.e. natural products) but also opens up new possibilities for the preparation of non-natural analogues.

Total synthesis of erythronolide A

-